There is a high incidence of gastric carcinoma in the coloured population of the Western Cape. Diagnostic tests other than barium meal examination or gastroscopy were investigated. In this study 50 patients were assessed and grouped according to the gastroscopic and histological findings. Twenty-five patients with gastric carcinoma and 25 with benign gastric ulcer and/or chronic atrophic gastritis and/or intestinal metaplasia were tabulated. The gastric juice and plasma carcino-embryonic antigen (CEA) levels were evaluated and compared in the two groups. The gastric juice CEA level was more useful than the plasma CEA level as an aid in diagnosing malignant gastric lesions. No correlation was evidence between CEA values and the extent of the gastric carcinoma and or histological typing. An elevated gastric juice CEA level was an additional aid in diagnosing gastric carcinoma. Markedly elevated values may also identify the high-risk patient who is prone to develop gastric carcinoma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Optimizing T cell inflamed signature through a combination biomarker approach for predicting immunotherapy response in NSCLC.
Sci Rep
December 2024
Interventional Oncology, Johnson & Johnson Enterprise Innovation, Inc, 10th Floor 255 Main St, 02142, Cambridge, Boston, MA, USA.
The introduction of anti-PD-1/PD-L1 therapies revolutionized treatment for advanced non-small cell lung cancer (NSCLC), yet response rates remain modest, underscoring the need for predictive biomarkers. While a T cell inflamed gene expression profile (GEP) has predicted anti-PD-1 response in various cancers, it failed in a large NSCLC cohort from the Stand Up To Cancer-Mark (SU2C-MARK) Foundation. Re-analysis revealed that while the T cell inflamed GEP alone was not predictive, its performance improved significantly when combined with gene signatures of myeloid cell markers.
View Article and Find Full Text PDFAssociation of PD-L1 positivity with Epstein Barr virus infection and microsatellite instability in gastric carcinomas with lymphoid stroma.
Sci Rep
December 2024
Department of Internal Medicine, Jeju National University Hospital, Jeju-si, South Korea.
Gastric carcinoma with lymphoid stroma (GCLS) is characterized by dense intra-and peritumoral lymphocytic infiltration and a high rate of Epstein Barr Virus (EBV) infection, suggesting being a promising candidate for immunotherapy. We investigated correlations between PD-L1 expression and clinicopathologic factors, including EBV positivity and microsatellite instability (MSI) status in GCLSs. The study included resected 214 GCLSs and 300 gastric adenocarcinomas (GACs) for control.
View Article and Find Full Text PDFA cerebral clue in the stomach: Brain lesion leads to discovery of hidden gastric cancer.
Int J Surg Case Rep
December 2024
Department of Radio Oncology, School of Medicine Cancer Prevention Research Center Seyyed Al-Shohada Hospital Isfahan University of Medical Sciences, Iran. Electronic address:
Introduction And Importance: Brain metastases from gastric adenocarcinoma are exceptionally rare, comprising only 0.1-0.16 % of all brain metastases.
View Article and Find Full Text PDFAnalysis of ROMO1 Expression Levels and Its Oncogenic Role in Gastrointestinal Tract Cancers.
Curr Issues Mol Biol
December 2024
Department of Medical Biochemistry, Trabzon Kanuni Health Practice and Research Hospital, Trabzon Faculty of Medicine, University of Health Sciences, Trabzon 61250, Turkey.
Gastrointestinal tract cancers account for approximately one-third of cancer-related deaths. Early diagnosis and effective treatment are the most important ways to prevent cancer-related morbidity and mortality. ROMO1 has been shown to play an important role in many types of cancer.
View Article and Find Full Text PDFCanadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma.
Curr Oncol
December 2024
Unity Health Toronto, University of Toronto, Toronto, ON M5B 1W8, Canada.
Gastric cancer is common globally and has a generally poor prognosis with a low 5-year survival rate. Targeted therapies and immunotherapies have improved the treatment landscape, providing more options for efficacious treatment. The use of these therapies requires predictive biomarker testing to identify patients who can benefit from their use.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!